Cue Biopharma Implements 1-for-30 Reverse Stock Split to Meet Nasdaq Listing Requirements

summarizeSummary

Cue Biopharma, Inc. has filed a Certificate of Amendment to effect a 1-for-30 reverse stock split, effective April 23, 2026, to comply with Nasdaq's minimum bid price requirement.

check_boxKey Events

• Reverse Stock Split Implemented

  Cue Biopharma, Inc. filed a Certificate of Amendment to its Certificate of Incorporation, implementing a 1-for-30 reverse stock split of its common stock.

• Effective Date and Trading

  The reverse stock split will be effective at 5:00 p.m. Eastern Time on April 23, 2026, with post-split trading expected to begin on April 24, 2026, under the existing 'CUE' symbol.

• Nasdaq Compliance Objective

  The primary purpose of the reverse stock split is to bring the company into compliance with the Nasdaq Capital Market's minimum bid price requirement, addressing a previously reported delisting threat.

• Impact on Securities

  All outstanding stock options and warrants will be proportionately adjusted, reducing the number of shares issuable upon exercise and increasing their exercise price. The number of authorized shares remains unchanged.

auto_awesomeAnalysis

This filing confirms the implementation of a 1-for-30 reverse stock split, a critical action for Cue Biopharma to regain compliance with Nasdaq's minimum bid price requirement. This follows the shareholder approval on April 13, 2026, and directly addresses the previously disclosed Nasdaq delisting threat and substantial doubt about the company's ability to continue as a going concern. While necessary for continued listing, reverse stock splits are generally viewed negatively by the market as they often signal financial distress and can lead to further share price volatility. Investors should monitor the stock's performance post-split and the company's progress in addressing its underlying financial challenges.